Gas-phase dissociation pathways of Beta-2 agonists

被引:4
作者
Carlo, Matthew J. [1 ]
York, Peyton M. [2 ]
Patrick, Amanda L. [1 ]
机构
[1] Mississippi State Univ, Dept Chem, Mississippi State, MS 39762 USA
[2] Mississippi State Univ, Dept Biochem, Mississippi State, MS 39762 USA
基金
美国国家科学基金会;
关键词
Performance-enhancing drugs; DFT; CID-MS; Unimolecular dissociation; MASS-SPECTROMETRY; SALBUTAMOL;
D O I
10.1016/j.ijms.2021.116548
中图分类号
O64 [物理化学(理论化学)、化学物理学]; O56 [分子物理学、原子物理学];
学科分类号
070203 ; 070304 ; 081704 ; 1406 ;
摘要
Beta-2 agonists are widely used for the treatment of asthma and other respiratory conditions. These same drugs, however, may also be taken with the aim of gaining an unfair advantage in sports competition, thus they are controlled under anti-doping initiatives. While there are several analytical protocols relying on MS/MS to identify various molecules in this class, relatively little work has been done on unraveling the underlying gas-phase dissociation chemistry for this class of molecules. Here, we apply collision-induced dissociation mass spectrometry (CID-MS) to a group of beta-2 agonists to explore characteristic dissociation pathways and we perform complementary density functional theory calcu-lations to better understand the underlying chemistry and the associated theoretical thermodynamics. Common dissociation pathways include one or more losses of water, and cleavage at the amine nitrogen is common, sometimes with the observance of complementary charge-retention pairs. In the case of more complex molecules, additional losses are observed, which lend insights into their specific struc-tures. These various pathways are discussed in detail for protonated isoetharine, salbutamol, formoterol, and salmeterol. The goal of this work is to contribute to a foundation of knowledge on the dissociation pathways of pharmaceuticals, especially those regulated as performance enhancing drugs. (c) 2021 Elsevier B.V. All rights reserved.
引用
收藏
页数:9
相关论文
共 33 条
[1]   Gabedit-A Graphical User Interface for Computational Chemistry Softwares [J].
Allouche, Abdul-Rahman .
JOURNAL OF COMPUTATIONAL CHEMISTRY, 2011, 32 (01) :174-182
[2]   HPLC-high-resolution time-of-flight mass spectrometry: Identification and determinarion of β-agonists in food and feed [J].
Amelin, V. G. ;
Korotkov, A. I. ;
Andoralov, A. M. .
JOURNAL OF ANALYTICAL CHEMISTRY, 2016, 71 (06) :598-604
[3]  
[Anonymous], 2020, WORLD ANTIDOPING COD
[4]  
Billington C.K., 2017, B2 AGONISTS PHARM TH
[5]   Development and validation of an UHPLC-MS/MS method for β2-agonists quantification in human urine and application to clinical samples [J].
Bozzolino, Cristina ;
Leporati, Marta ;
Gani, Federica ;
Ferrero, Cinzia ;
Vincenti, Marco .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2018, 150 :15-24
[6]   Source discrimination of drug residues in wastewater: The case of salbutamol [J].
Depaolini, Andrea Re ;
Fattore, Elena ;
Cappelli, Francesca ;
Pellegrino, Raffaele ;
Castiglioni, Sara ;
Zuccato, Ettore ;
Fanelli, Roberto ;
Davoli, Enrico .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2016, 1023 :62-67
[7]  
DOERING WV, 1954, J AM CHEM SOC, V76, P3203
[8]   β2-agonists at the Olympic Games [J].
Fitch, Kenneth D. .
CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY, 2006, 31 (2-3) :259-268
[9]   Sports doping: Emerging designer and therapeutic β2-agonists [J].
Fragkaki, A. G. ;
Georgakopoulos, C. ;
Sterk, S. ;
Nielen, M. W. F. .
CLINICA CHIMICA ACTA, 2013, 425 :242-258
[10]  
Frisch M. J., GAUSSIAN DEV VERSION